Efficacy of Clarithromycin Depends on the Bacterial Density in Clarithromycin-Heteroresistant Helicobacter pylori Infections: An In Situ Detected Susceptibility and Quantitative Morphometry-Based Retrospective Study
Open Access
- 29 June 2021
- journal article
- research article
- Published by Frontiers Media SA in Pathology and Oncology Research
- Vol. 27, 1609863
- https://doi.org/10.3389/pore.2021.1609863
Abstract
The global rise in clarithromycin (Cla) resistance is considered to be the main contributor of Helicobacter pylori (Hp) eradication failures. In nearly half of the Cla-resistant Hp infections, Cla-susceptible bacteria are simultaneously present with the Cla-resistant ones (Cla-heteroresistance). The proportion of resistant bacteria in the bacterial population (R-fraction) and its predictive role for the use of Cla-based therapies in Cla-heteroresistant infections has not yet been investigated. Our retrospective study analyzed gastric biopsy samples of 62 Hp-positive patients with Cla-heteroresistant infection. Fluorescence In Situ Hybridization technique was used to visualize the coexistence of resistant and susceptible bacteria within one tissue sample. R-fraction was quantified on multichannel microimages by digital morphometry. Resistant bacteria had a patchy distribution within the whole bacterial population causing high diversity among the investigated areas. Patients were subdivided into two major groups according to whether a Cla-based eradication attempt was conducted before or after the biopsy sampling. R-fraction was significantly lower among cases having only one previous Cla-based eradication attempt vs. those that had multiple previous eradications, including at least one Cla-containing therapy (0.41 vs. 0.89, p = 0.0308). Majority of the patients without previous eradication attempt had successful eradication with Cla-containing regimen (59.26%), verified by a negative 13C-urea breath test or control biopsy. Multivariable model indicated that the therapeutic outcome using Cla-based regimens depended on the bacterial density rather than the R-fraction. Our study raises the potential use of Cla-containing eradication therapies in certain Cla-heteroresistant Hp infections, taking into account the possible predictive role of bacterial density.Keywords
Funding Information
- Emberi Eroforrások Minisztériuma
- Nemzeti Kutatási Fejlesztési és Innovációs Hivatal
- Ministry for Innovation and Technology
- Semmelweis Egyetem
This publication has 43 references indexed in Scilit:
- Helicobacter pylori treatment in the era of increasing antibiotic resistanceGut, 2010
- Phenotypic and genotypic Helicobacter pylori clarithromycin resistance and therapeutic outcome: benefits and limitsJournal of Antimicrobial Chemotherapy, 2009
- Helicobacter pylori amoxicillin heteroresistance due to point mutations in PBP-1A in isogenic isolatesJournal of Antimicrobial Chemotherapy, 2008
- Helicobacter pyloriDetection and Antimicrobial Susceptibility TestingClinical Microbiology Reviews, 2007
- H pylori antibiotic resistance: prevalence, importance, and advances in testingGut, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003
- Rapid and Accurate Determination of Genotypic Clarithromycin Resistance in Cultured Helicobacter pylori by Fluorescent In Situ HybridizationJournal of Clinical Microbiology, 2001
- Clarithromycin for Helicobacter pylori infectionExpert Opinion on Pharmacotherapy, 2000
- In situ hybridization for detection of Helicobacter pylori in paraffin sections: T.J. Karttunen, F.A.K. El-Zaatari, R.M. Genta, C. Hachem, D.Y. Graham. Departments of Medicine and Pathology, VAMC and Baylor College of Medicine, Houston, TXGastroenterology, 1995
- Clarithromycin for the Eradication of Helicobacter PyloriJournal of Clinical Gastroenterology, 1993